Next-Generation Gadolinium-Based Contrast Agents: Advancing MRI ++++

Optimizing Breast MRI Surveillance in High-Risk Patients: Strategies for Repeat Imaging Excellence: A MEDSCAPE RADTECH ACTIVITY https://www.medscape.org/viewarticle/optimizing-breast-mri-surveillance-high-risk-patients-2026a1000nh4?page=1&src=wnl_tpal_260731_mscpedu&uac=148436CN&impID=8556438 Optimizing Breast MRI Surveillance in High-Risk Patients: Strategies for Repeat Imaging Excellence: A MEDSCAPE RADTECH ACTIVITY Authors: Katja Pinker-Domenig, MD, PhD; Ritse M. Mann, MD, PhD Next-Generation Gadolinium-Based Contrast Agents: Advancing MRI CME / ABIM MOC Next-Generation Gadolinium-Based Contrast Agents: Advancing MRI Authors: Max Wintermark, MD, MS, MBA https://www.medscape.org/viewarticle/next-generation-gadolinium-based-contrast-agents-advancing-2026a1000l3e?page=1&src=wnl_tpal_260731_mscpedu&uac=148436CN&impID=8556438 Next-Generation Gadolinium-Based Contrast Agents: Advancing MRI for RadTech Next-Generation Gadolinium-Based Contrast Agents: Advancing MRI for RadTech Authors: Max Wintermark, MD, MS, MBA https://www.medscape.org/viewarticle/gadolinium-based-contrast-agents-advancing-radtech-2026a1000lss?page=1&src=wnl_tpal_260731_mscpedu&uac=148436CN&impID=8556438 Medscape Now! Hospital Readmissions 2026: Collaborative Approaches to Improve Patient Outcomes CME / ABIM MOC / CE Medscape Now! Hospital Readmissions 2026: Collaborative Approaches to Improve Patient Outcomes Authors: Blessing Ajayi, PA-C https://www.medscape.org/viewarticle/medscape-now-hospital-readmissions-2026-collaborative-2026a1000pa4?page=1&src=wnl_tpal_260731_mscpedu&uac=148436CN&impID=8556438

Interprofessional Approach to Adverse Event Care for the Patient With High-Risk Hormone Receptor-Positive/HER2-Negative Early Breast Cancer Authors: Jonathan Malara, PharmD, BCOP; Nelli Zafman, CRNP, MSN, AOCNP

https://www.medscape.org/viewarticle/interprofessional-approach-adverse-event-care-patient-high-2026a1000gez?page=1&src=mkmcmr_driv_stan_mscpedu_260731-OUS-HONC-interprofessional-approach-adverse-event-care-patient-high-2026a1000gez-cta&uac=148436CN

Expert Panel Decision Framework: Progressive Strategies for Managing HER2-Mutated Advanced NSCLC Authors: Charu Aggarwal, MD, MPH; Herbert H. Loong, MBBS, FRCP; Umberto Malapelle, PhD

https://www.medscape.org/viewarticle/expert-panel-decision-framework-progressive-strategies-2026a1000diy?page=1&src=mkmcmr_driv_stan_mscpedu_260801-OUS-HONC-expert-panel-decision-framework-progressive-strategies-2026a1000diy-cta&uac=148436CN

Community of Learning: Perinatal Mental Health Conditions in the Outpatient Setting

https://saferbirth.org/events/community-of-learning-perinatal-mental-health-conditions-in-the-outpatient-setting/?utm_medium=email&utm_source=govdelivery Integrating Maternal Mental Health Care into Maternity Care Community of Learning Monthly sessions from August 11, 2026 through January 12, 2027 The Policy Center for Maternal Mental Health announced the launch of a six-part national community of learning, in collaboration with the Alliance for Innovation on Maternal Health (AIM) Technical Assistance Center, designed to help state leaders support obstetric clinics in integrating perinatal mental health care into routine maternity care throughout pregnancy and the postpartum period. The Community of Learning will run from August 11th through January 12th and is designed for entities participating in the AIM, including state hospital associations, state health departments, or state perinatal quality collaboratives.

HHS & VA Announce Bold, Comprehensive Partnership to Advance Rapid-Acting Mental Health Treatments for Veterans

https://www.hhs.gov/press-room/hhs-va-partner-advance-psychedelic-therapies-veterans.html?utm_medium=email&utm_source=govdelivery The U.S. Department of Health and Human Services (HHS) and the U.S. Department of Veterans Affairs (VA) today entered into a Memorandum of Understanding (MOU) to strengthen collaboration on the research, clinical development, and, if approved by the U.S. Food and Drug Administration (FDA), the responsible deployment of future rapid-acting psychedelic drug products for veterans with serious mental health conditions. Under the agreement, HHS and VA will coordinate workforce training, develop evidence-based clinical protocols, support research and real-world evidence generation, and prepare the VA healthcare system to responsibly implement future FDA-approved rapid-acting psychiatric drug products as they become available.

Make Hospital Food Healthier Pledge

https://www.hhs.gov/maha-hospital-pledge/index.html?utm_medium=email&utm_source=govdelivery The U.S. spends approximately $5 trillion each year on health care, with 90% of those costs driven by chronic disease. Hospitals do more than treat illness—they influence recovery, support long-term health, and help patients manage chronic conditions.The Make Hospital Food Healthier Pledge challenges hospitals to put nutrition at the center of care. By reviewing and aligning food service practices with the Dietary Guidelines for Americans, hospitals can improve patient outcomes, reduce complications, and promote healthier communities long after patients leave their care.

FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).

Multimodal treatment achieves durable radiologic remission in adult primary pulmonary embryonal rhabdomyosarcoma Taikang Yao, Sidney Wen, Zhenchao Wu, Jinshu Zhao, Guolin Alexander Wen Volume 2, Issue 3

https://www.academia.edu/journals/academia-immunity-and-disease/articles?source=journal-top-nav Introduction: Primary pulmonary rhabdomyosarcoma (PPRMS) is an exceedingly rare thoracic sarcoma in adults, and evidence-based treatment strategies are not established. Case presentation: A 71-year-old Han Chinese man with prior esophageal rupture repair and no smoking history was found to have a right lower hilar mass. Baseline clinical assessment showed preserved self-care capacity, with a Karnofsky Performance Status of 80%. Bronchoscopy identified a friable cauliflower-like endobronchial neoplasm obstructing the right lower lobe bronchus. Biopsy and immunohistochemistry showed embryonal-type PPRMS, including focal/partial positivity for myogenic differentiation 1 (MyoD1), myogenin, and desmin and a Ki-67 index of approximately 90%. The tumor was clinically staged as cT2aN1M0 (Stage IIB), although the hilar node and small pulmonary nodules were not pathologically confirmed and positron emission tomography-computed tomography (PET-CT) was not performed. Because surgery was not feasible, the patient received cisplatin, nab-paclitaxel, and adebrelimab every 21 days for six cycles plus curative-intent intensity-modulated radiotherapy (66 Gy in 30 fractions) between cycles 4 and 5. Serial chest computed tomography (CT) showed near-complete resolution of the primary mass and improvement in hilar adenopathy, and bronchoscopic follow-up approximately 9 months after diagnosis showed no endobronchial neoplasm. Patient-assessed symptom burden during initial treatment consisted mainly of manageable nausea and fatigue. A later pulmonary event caused dyspnea with routine activities and improved after oxygen support and glucocorticoid-based management. Conclusions: This case documents durable clinical and radiologic remission after individualized multimodal treatment in an elderly patient with adult PPRMS. The observation is hypothesis-generating and cannot establish the independent efficacy of chemotherapy, programmed death-ligand 1 (PD-L1) blockade, or radiotherapy. Missing PET-CT, nodal or pulmonary-nodule biopsy confirmation, PD-L1 testing, and molecular profiling limit biological interpretation. https://www.academia.edu/3143-0481/2/3/10.20935/AcadImmunoDis8403